Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia

Publication date

2022-04-15

Authors

van der Vaart, Thomas
Prins, Jan M
Soetekouw, Robin
van Twillert, Gitte
Veenstra, Jan
Herpers, Bjorn L
Rozemeijer, Wouter
Jansen, Rogier R
Bonten, MarcISNI 0000000034264654
van der Meer, Jan T M

Editors

Advisors

Supervisors

Document Type

Article

Collections

Open Access logo

License

cc_by_nc_nd

Abstract

BACKGROUND: Staphylococcus aureus bacteremia (SAB) is in 10% to 20% of cases complicated by infective endocarditis. Clinical prediction scores may select patients with SAB at highest risk for endocarditis, improving the diagnostic process of endocarditis. We compared the accuracy of the Prediction Of Staphylococcus aureus Infective endocarditiseTime to positivity, Iv drug use, Vascular phenomena, preExisting heart condition (POSITIVE), Predicting Risk of Endocarditis Using a Clinical Tool (PREDICT), and VIRSTA scores for classifying the likelihood of endocarditis in patients with SAB. METHODS: Between August 2017 and September 2019, we enrolled consecutive adult patients with SAB in a prospective cohort study in 7 hospitals in the Netherlands. Using the modified Duke Criteria for definite endocarditis as reference standard, sensitivity, specificity, negative predictive (NPV), and positive predictive values were determined for the POSITIVE, PREDICT, and VIRSTA scores. An NPV of at least 98% was considered safe for excluding endocarditis. RESULTS: Of 477 SAB patients enrolled, 33% had community-acquired SAB, 8% had a prosthetic valve, and 11% a cardiac implantable electronic device. Echocardiography was performed in 87% of patients, and 42% received transesophageal echocardiography (TEE). Eighty-seven (18.2%) had definite endocarditis. Sensitivity was 77.6% (65.8%-86.9%), 85.1% (75.8%-91.8%), and 98.9% (95.7%-100%) for the POSITIVE (n = 362), PREDICT, and VIRSTA scores, respectively. NPVs were 92.5% (87.9%-95.8%), 94.5% (90.7%-97.0%), and 99.3% (94.9%-100%). For the POSITIVE, PREDICT, and VIRSTA scores, 44.5%, 50.7%, and 70.9% of patients with SAB, respectively, were classified as at high risk for endocarditis. CONCLUSIONS: Only the VIRSTA score had an NPV of at least 98%, but at the expense of a high number of patients classified as high risk and thus requiring TEE. CLINICAL TRIALS REGISTRATION: Netherlands Trial Register code 6669.

Keywords

Adult, Bacteremia/complications, Endocarditis, Bacterial/complications, Endocarditis/complications, Humans, Prospective Studies, Staphylococcal Infections/complications, Staphylococcus aureus, Staphylococcus aureus bacteremia, echocardiography, endocarditis, risk stratification, Journal Article

Citation

van der Vaart, T W, Prins, J M, Soetekouw, R, van Twillert, G, Veenstra, J, Herpers, B L, Rozemeijer, W, Jansen, R R, Bonten, M J M & van der Meer, J T M 2022, 'Prediction rules for ruling out endocarditis in patients with Staphylococcus aureus bacteremia', Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, vol. 74, no. 8, pp. 1442-1449. https://doi.org/10.1093/cid/ciab632